---
title: "Damora Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295446054.md"
description: "The Phase 1/1b CLARITY-101 clinical trial has been launched to study DMR-001 in individuals suffering from mutant calreticulin (mutCALR)-driven essential thrombocythemia (ET) and myelofibrosis (MF). This trial aims to assess the effectiveness and safety of DMR-001 in treating these conditions."
datetime: "2026-08-10T20:07:57.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295446054.md)
  - [en](https://longbridge.com/en/news/295446054.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295446054.md)
---

# Damora Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights

The Phase 1/1b CLARITY-101 clinical trial has been launched to study DMR-001 in individuals suffering from mutant calreticulin (mutCALR)-driven essential thrombocythemia (ET) and myelofibrosis (MF). This trial aims to assess the effectiveness and safety of DMR-001 in treating these conditions.

### Related Stocks

- [DMRA.US](https://longbridge.com/en/quote/DMRA.US.md)

## Related News & Research

- [Damora Therapeutics posts corporate deck on mutCALR-targeted therapies for myeloproliferative neoplasms](https://longbridge.com/en/news/295448291.md)
- [Damora Therapeutics starts Phase 1/1b CLARITY-101 trial of DMR-001 in mutant CALR-driven ET, myelofibrosis](https://longbridge.com/en/news/294963179.md)
- [Analyst Reiterates Buy on Damora Therapeutics, Maintains $45 Price Target on Differentiated Clinical Strategy](https://longbridge.com/en/news/295521208.md)
- [12:14 ETAs Spinal Muscular Atrophy (SMA) Awareness Month Begins, Cure SMA Spotlights Progress and Persistent Gaps in SMA Care](https://longbridge.com/en/news/295258218.md)
- [Damora Therapeutics: Buy Rating Reaffirmed on Differentiated ET/MF Candidate and $50 Price Target](https://longbridge.com/en/news/293852487.md)